Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents (DATES)

Jordan Collaborating Cardiology Group

Status: Enrolling

Conditions: Major Bleeding; Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Study type: Observational

Funder types: Other

Identifiers

NCT07039149

DATES.2.25/irbIH1725

Details and patient eligibility

About

This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab. What is the outcome when the 2 agents are given n the ER?

Full description

Dual antiplatelet therapy (DAPT) is a standard treatment in ST-elevation myocardial infarction (STEMI) and non-ST-segment-elevation acute coronary syndrome (NSTEACS) . However, the timing of initiation of DAPT in the Emergency Department (ED) has been defined by recent western guidelines (i.e., aspirin in the ER and and a second AP agent when the coronary anatomy has been denied in the cath lab. This strategy aims at decreasing the incidence of bleeding events. However, patients with ACS in the Middle East are younger than those in the West and have lower bleeding risk. The purpose of this study is to evaluate the incidence of major bleeding in patients who received DAPT in the ED according to the discretion of the treating physician.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients
• Presenting with acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, and unstable angina).
• Antiplatelet medication (s) prescribed during index admission to hospital.
• Willingness of the patient to be called for follow up up to 1 year after index hospitalization.

Exclusion criteria

• Non cardiac chest pain.
• No administration of antiplatelet agents during hospitalization.
• Refusal of contact for follow up.

Trial design

200 participants in 1 patient group

Adult patients admitted for acute coronary syndrome via the ED

Description:

Patients with ACS presenting to the ED with a planned coronary angiography for possible coronary revascularization who get aspirin in the ED will be evaluated for bleeding and major cardiovascular events when they receive a second antiplatelet agent in the ED compared with in the cath lab.